Sedide Ozturk

Sedide Ozturk's work experience includes roles such as Director of Corporate Development at Freenome, where they completed the company's first acquisition. Prior to that, they held the position of Director of Business Development at Roche from 2020 to 2022. Sedide also worked as a Sales and Marketing Consultant at Roche Diagnostics Subregion Northwestern Europe, where their responsibilities included market assessment and enhancing customer relationships. At Roche Sequencing, they served as a Group Leader, leading teams in forming partnerships and developing commercial strategies. Sedide has also worked as a Principle Scientist at Ventana Medical Systems and as a Postdoctoral Researcher at Harvard Medical School, where they led collaborations to develop new technologies using next-generation sequencing.

Sedide Ozturk completed their education in a chronological order. Sedide obtained a Bachelor's of Science degree in Engineering from Orta Doğu Teknik Üniversitesi/ Middle East Technical University in 2001. Sedide then pursued a Ph.D. in Molecular Genetics, Microbiology, and Immunology from Rutgers University from 2003 to 2008. Following that, they engaged in post-doctoral studies in Systems Biology at Harvard Medical School from 2008 to 2012. More recently, they acquired an MBA Essentials Certificate from The London School of Economics and Political Science (LSE) in 2021-2022. Additionally, they hold various certifications, including Empowered: Product Leadership from Silicon Valley Product Group and Platform Design Certification from Boundaryless - Platform Design Toolkit.